{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:07:14Z","timestamp":1789092434467,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":78,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01246-x","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:07:22Z","timestamp":1782389242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor lymph node metastasis chip reveals that the NECTIN3-TIGIT axis promotes melanoma metastasis by enhancing treg cell function and inducing CD8+ T cell exhaustion"],"prefix":"10.1007","volume":"49","author":[{"given":"Cuihao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"10400","key":"1246_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0140-6736(23)00821-8","volume":"402","author":"G.V. Long","year":"2023","unstructured":"G.V. Long, S.M. Swetter, A.M. Menzies, J.E. Gershenwald, R.A. Scolyer, Cutaneous melanoma. Lancet 402(10400), 485\u2013502 (2023). https:\/\/doi.org\/10.1016\/s0140-6736(23)00821-8","journal-title":"Lancet"},{"key":"1246_CR2","doi-asserted-by":"publisher","unstructured":"J. Burshtein et al., Advances in the noninvasive diagnosis of melanoma\u201440 years beyond the ABCDs. CA Cancer J. Clinicians. 76(1), e70065 (2026). https:\/\/doi.org\/10.3322\/caac.70065","DOI":"10.3322\/caac.70065"},{"issue":"30","key":"1246_CR3","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/jco.23.01136","volume":"41","author":"R. Seth","year":"2023","unstructured":"R. Seth et al., Systemic therapy for melanoma: ASCO guideline update. JCO. 41(30), 4794\u20134820 (2023). https:\/\/doi.org\/10.1200\/jco.23.01136","journal-title":"JCO"},{"issue":"23","key":"1246_CR4","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","volume":"384","author":"B.D. Curti","year":"2021","unstructured":"B.D. Curti, M.B. Faries, Recent Advances in the treatment of melanoma. N. Engl. J. Med. 384(23), 2229\u20132240 (2021). https:\/\/doi.org\/10.1056\/NEJMra2034861","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"1246_CR5","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1001\/jama.2025.13074","volume":"334","author":"U.M. Joshi","year":"2025","unstructured":"U.M. Joshi, M. Kashani-Sabet, J.M. Kirkwood, cutaneous melanoma: a review. JAMA 334(23), 2113\u20132125 (2025). https:\/\/doi.org\/10.1001\/jama.2025.13074","journal-title":"JAMA"},{"issue":"4","key":"1246_CR6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"22","author":"S. Kalaora","year":"2022","unstructured":"S. Kalaora, A. Nagler, J.A. Wargo, Y. Samuels, Mechanisms of immune activation and regulation: lessons from melanoma. Nat. Rev. Cancer 22(4), 195\u2013207 (2022). https:\/\/doi.org\/10.1038\/s41568-022-00442-9","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1246_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W. Guo","year":"2021","unstructured":"W. Guo, H. Wang, C. Li, Signal pathways of melanoma and targeted therapy. Sig. Transduct. Target Ther. 6(1), 424 (2021). https:\/\/doi.org\/10.1038\/s41392-021-00827-6","journal-title":"Sig Transduct Target Ther."},{"issue":"11","key":"1246_CR8","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2025.01.009","volume":"35","author":"J. Pozniak","year":"2025","unstructured":"J. Pozniak, J.C. Marine, Decoding melanoma\u2019s cellular mosaic to unlock immunotherapy potential. Trends. Cell. Biol. 35(11), 911\u2013921 (2025). https:\/\/doi.org\/10.1016\/j.tcb.2025.01.009","journal-title":"Trends Cell. Biol."},{"key":"1246_CR9","doi-asserted-by":"publisher","unstructured":"A. Tasdogan et al., Cutaneous melanoma. Nat. Rev. Dis. Primers 11(1) (2025). https:\/\/doi.org\/10.1038\/s41572-025-00603-8","DOI":"10.1038\/s41572-025-00603-8"},{"issue":"1","key":"1246_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L. Cai","year":"2023","unstructured":"L. Cai, Y. Li, J. Tan, L. Xu, Y. Li, Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J. Hematol. Oncol. 16(1), 101 (2023). https:\/\/doi.org\/10.1186\/s13045-023-01499-1","journal-title":"J. Hematol. Oncol."},{"key":"1246_CR11","doi-asserted-by":"publisher","unstructured":"X. Chu, W. Tian, Z. Wang, J. Zhang, R. Zhou, Co-inhibition of TIGIT and PD-1\/PD-L1 in cancer immunotherapy: mechanisms and clinical trials. Mol. Cancer 22(1), (2023). https:\/\/doi.org\/10.1186\/s12943-023-01800-3","DOI":"10.1186\/s12943-023-01800-3"},{"issue":"2","key":"1246_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N. Joller","year":"2024","unstructured":"N. Joller, A.C. Anderson, V.K. Kuchroo, LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity 57(2), 206\u2013222 (2024). https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010","journal-title":"Immunity"},{"issue":"1","key":"1246_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L. Kraehenbuehl","year":"2022","unstructured":"L. Kraehenbuehl, C.H. Weng, S. Eghbali, J.D. Wolchok, T. Merghoub, Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19(1), 37\u201350 (2022). https:\/\/doi.org\/10.1038\/s41571-021-00552-7","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"1246_CR14","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.ccell.2021.07.007","volume":"39","author":"W.A. Freed-Pastor","year":"2021","unstructured":"W.A. Freed-Pastor et al., The CD155\/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell. 39(10), 1342\u20131360.e14 (2021). https:\/\/doi.org\/10.1016\/j.ccell.2021.07.007","journal-title":"Cancer Cell."},{"key":"1246_CR15","doi-asserted-by":"crossref","unstructured":"X. Chu, W. Tian, Z. Wang, J. Zhang, R. Zhou, Mol Cancer 22(101), (2023)","DOI":"10.1186\/s12943-023-01800-3"},{"key":"1246_CR16","doi-asserted-by":"publisher","unstructured":"P. Zhang et al., Targeting TIGIT for cancer immunotherapy: recent advances and future directions. Biomark Res. 12(1), (2024). https:\/\/doi.org\/10.1186\/s40364-023-00543-z","DOI":"10.1186\/s40364-023-00543-z"},{"issue":"1","key":"1246_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","volume":"9","author":"N. Yin","year":"2024","unstructured":"N. Yin et al., Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Sig. Transduct. Target Ther. 9(1), 126 (2024). https:\/\/doi.org\/10.1038\/s41392-024-01826-z","journal-title":"Sig Transduct Target Ther."},{"issue":"2","key":"1246_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41577-025-01222-w","volume":"26","author":"F. Fallarino","year":"2026","unstructured":"F. Fallarino, C.U. Blank, Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape. Nat. Rev. Immunol. 26(2), 152\u2013162 (2026). https:\/\/doi.org\/10.1038\/s41577-025-01222-w","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"1246_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41568-023-00565-7","volume":"23","author":"P.P. Centeno","year":"2023","unstructured":"P.P. Centeno, V. Pavet, R. Marais, The journey from melanocytes to melanoma. Nat. Rev. Cancer 23(6), 372\u2013390 (2023). https:\/\/doi.org\/10.1038\/s41568-023-00565-7","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1246_CR20","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s43018-024-00794-1","volume":"5","author":"B.M. Robertson","year":"2024","unstructured":"B.M. Robertson, M.E. Fane, A.T. Weeraratna, V.W. Rebecca, Determinants of resistance and response to melanoma therapy. Nat. Cancer. 5(7), 964\u2013982 (2024). https:\/\/doi.org\/10.1038\/s43018-024-00794-1","journal-title":"Nat. Cancer."},{"issue":"10304","key":"1246_CR21","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/s0140-6736(21)01206-x","volume":"398","author":"M.S. Carlino","year":"2021","unstructured":"M.S. Carlino, J. Larkin, G.V. Long, Immune checkpoint inhibitors in melanoma. Lancet 398(10304), 1002\u20131014 (2021). https:\/\/doi.org\/10.1016\/s0140-6736(21)01206-x","journal-title":"Lancet"},{"issue":"6","key":"1246_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41571-023-00760-3","volume":"20","author":"M.W. Lucas","year":"2023","unstructured":"M.W. Lucas, J.M. Versluis, E.A. Rozeman, C.U. Blank, Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nat. Rev. Clin. Oncol. 20(6), 408\u2013422 (2023). https:\/\/doi.org\/10.1038\/s41571-023-00760-3","journal-title":"Nat Rev Clin Oncol."},{"issue":"5","key":"1246_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"A.C. Huang","year":"2022","unstructured":"A.C. Huang, R. Zappasodi, A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23(5), 660\u2013670 (2022). https:\/\/doi.org\/10.1038\/s41590-022-01141-1","journal-title":"Nat. Immunol."},{"issue":"5","key":"1246_CR24","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","volume":"20","author":"L.A. Low","year":"2021","unstructured":"L.A. Low, C. Mummery, B.R. Berridge, C.P. Austin, D.A. Tagle, Organs-on-chips: into the next decade. Nat. Rev. Drug. Discov. 20(5), 345\u2013361 (2021). https:\/\/doi.org\/10.1038\/s41573-020-0079-3","journal-title":"Nat Rev Drug. Discov."},{"key":"1246_CR25","doi-asserted-by":"publisher","first-page":"113798","DOI":"10.1016\/j.addr.2021.05.008","volume":"175","author":"N. Del Piccolo","year":"2021","unstructured":"N. Del Piccolo et al., Tumor-on-chip modeling of organ-specific cancer and metastasis. Adv. Drug. Deliv. Rev. 175, 113798 (2021). https:\/\/doi.org\/10.1016\/j.addr.2021.05.008","journal-title":"Adv Drug. Deliv Rev."},{"issue":"3","key":"1246_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","volume":"55","author":"K.L. Banta","year":"2022","unstructured":"K.L. Banta, X. Xu, A.S. Chitre, A. Au-Yeung, C. Takahashi, W.E. O\u2019Gorman, T.D. Wu, S. Mittman, R. Cubas, L. Comps-Agrar, A. Fulzele, E.J. Bennett, J.L. Grogan, E. Hui, E.Y. Chiang, I. Mellman, Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity 55(3), 512\u2013526.e9 (2022). https:\/\/doi.org\/10.1016\/j.immuni.2022.02.005","journal-title":"Immunity"},{"key":"1246_CR27","doi-asserted-by":"publisher","unstructured":"E.Y. Chiang, I. Mellman, TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J. Immunother. Cancer. 10(4), e004711 (2022). https:\/\/doi.org\/10.1136\/jitc-2022-004711","DOI":"10.1136\/jitc-2022-004711"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01246-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:45:30Z","timestamp":1789091130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01246-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01246-x","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"30 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This research does not involve experiments involving Animal subjects.","order":1,"name":"Ethics","label":"Ethic of animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Measures for Ethical Review of Biomedical Research Involving Human Subjects (China). The study was approved by the Chinese PLA General Hospital Ethics Committee (Approval Number: S2025-093\u201301, China), and all research subjects signed written informed consent forms.","order":2,"name":"Ethics","label":"Ethic of human participants","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All research subjects signed written informed consent forms.","order":3,"name":"Ethics","label":"Consent of patients","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}